C-reactive protein, interleukin-6 and the risk of colorectal cancer: a meta-analysis

Bo Zhou,Bin Shu,Jue Yang,Jing Liu,Tao Xi,Yingying Xing

DOI: https://doi.org/10.1007/s10552-014-0445-8

2014-01-01

Abstract:Purpose Many studies have evaluated the associations between pre-diagnostic circulating C-reactive protein (CRP), interleukin-6 (IL-6) and colorectal cancer risk, but their results are inconsistent. We therefore conducted a meta-analysis to investigate these associations. Methods A comprehensive literature search up to October 2013 was undertaken in PubMed. Pooled relative risk (RR) estimates and 95 % confidence intervals (CIs) were used to calculate estimated effect. Results Eighteen studies on CRP comprising a total of 4,706 colorectal cancer cases were included in this meta-analysis. The summary RR of colorectal cancer for one unit change in natural logarithm (ln) CRP was 1.12 [95 % CI (1.05–1.21)]. There was statistically significant heterogeneity among studies ( p = 0.006; I 2 = 51.7 %). After excluding the studies contributing most to the heterogeneity, summary estimate was essentially unchanged. In addition, the association was significant for colon cancer [RR = 1.13, 95 % CI (1.05–1.21)], not for rectal cancer [RR = 1.03, 95 % CI (0.90–1.17)]. We also found that CRP was significantly associated with increased risk of colorectal cancer among men, but not among women. There were six studies on IL-6 that involved a total of 1,068 colorectal cancer cases. The pooled RR of colorectal cancer for one unit change in ln IL-6 was 1.10 (95 % CI 0.88–1.36), and no statistically significant heterogeneity was found ( p = 0.175; I 2 = 34.8 %). Conclusion Our results suggest that pre-diagnostic circulating CRP is associated with increased risk of colorectal cancer. However, there is no significant association between IL-6 and colorectal cancer risk.